Drug Profile
Insulin lispro - Eli Lilly and Company
Alternative Names: Humalog; Humalog Junior KwikPen; Humalog N; Humalog U 200; insulin lispro injection - Eli Lilly and Company; LY 275585; LY-8888AX; Lys-B28, Pro-B29; LysproLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diabetes mellitus
Most Recent Events
- 05 Oct 2023 Clinical trials in Diabetes mellitus (Treatment-experienced) in France (SC) (NCT05893797)
- 15 Jun 2023 Eli Lilly and Company plans clinical trial for Type 1 diabetes mellitus and Type 2 diabetes mellitus (Treatment-experienced) (NCT05893797)
- 04 Oct 2021 Cipla in-licensed marketing rights from Eli Lilly and Company for insulin lispro in India